Enliven Therapeutics, Inc.

NasdaqGS ELVN

Enliven Therapeutics, Inc. Price to Book Ratio (P/B) on January 14, 2025

Enliven Therapeutics, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Enliven Therapeutics, Inc. 52-week high Price to Book Ratio (P/B) is 4.72 on July 26, 2024, which is NA below the current Price to Book Ratio (P/B).
Enliven Therapeutics, Inc. 52-week low Price to Book Ratio (P/B) is 2.96 on April 25, 2024, which is NA below the current Price to Book Ratio (P/B).
Enliven Therapeutics, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 3.85.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: ELVN

Enliven Therapeutics, Inc.

CEO	Mr. Samuel S. Kintz M.B.A.
IPO Date	March 12, 2020
Location	United States
Headquarters	6200 Lookout Road
Employees	46
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Key trends

Past 5 years